Propranolol Tablets manufacturers & suppliers

Propranolol Tablets

Form: Oral tablets

Strength: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg

Reference Brands: Inderal®(US & EU); Avlocardyl®(EU)

Category: Antipsychotropic Drugs

Propranolol tablets are FDA-approved in the United States for a wide range of indications including hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, migraine prophylaxis, and essential tremor. Regulatory requirements include GMP-compliant manufacturing, submission of bioequivalence data for generics, and adherence to labeling for cardiovascular safety and CNS effects. Propranolol is a non-selective beta-blocker, and all U.S. approvals must comply with pharmacovigilance and controlled substance exclusion. In the European Union, propranolol tablets are authorized under national marketing authorizations, with similar indications and requirements for Risk Management Plans (RMPs) and pharmacovigilance. For B2B sourcing and dossiers, visit Pharmatradz.com.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Risperidone Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Form: Long-Acting Injection

Reference Brands: Risperdal Consta(US &EU)

View Details
Zuclopenthixol Ong-Acting Im Injection (Depot)

Strength: 200 mg/mL, 500 mg/mL

Form: Long-acting IM Injection (Depot)

Reference Brands: Clopixol Depot®(US)

View Details
Zuclopenthixol Short-Acting Intramuscular Injection

Strength: 50 mg/mL

Form: Short-acting Intramuscular Injection

Reference Brands: Clopixol-Acuphase®

View Details
Zuclopenthixol Tablets

Strength: 10 mg, 25 mg, 40 mg

Form: Oral Tablets

Reference Brands: Clopixol®(EU)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.